Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Homeodomain-interacting protein kinase 2 (HIPK2) is a nuclear serine/threonine kinase of the subfamily of dual-specificity Yak1-related kinase proteins. HIPK2 was first described as a homeodomain-
interacting protein
kinase acting as a corepressor for homeodomain transcription factors. More recently, it was reported that HIPK2 plays a role in
p53
-mediated cellular apoptosis and could also participate in the regulation of the cell cycle. US11 protein of herpes simplex virus type 1 is a multifunctional protein involved in the regulation of several processes related to the survival of cells submitted to environmental stresses by mechanisms that are not fully elucidated. In an attempt to better understand the multiple functions of US11, we identified cellular binding partners of this protein by using the yeast two-hybrid system. We report that US11 interacts with HIPK2 through the PEST domain of HIPK2 and that this interaction occurs also in human cells. This interaction modifies the subcellular distribution of HIPK2 and protects the cell against the HIPK2-induced cell growth arrest.
...
PMID:US11 of herpes simplex virus type 1 interacts with HIPK2 and antagonizes HIPK2-induced cell growth arrest. 1499 Jul 17
Ubiquitin inhibitors act at many levels to enhance apoptosis signaling. For TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis signaling, there are at least five mechanisms by which apoptosis are regulated by the ubiquitin-proteasome pathway. First, proteasome inhibitors can decrease Fas-like inhibitor protein (FLIP) protein levels in tumors, resulting in increased apoptosis signaling due to increased caspase-8 activation. This appears to involve the ubiquitin ligase TNF receptor activation factor-2 (TRAF2) and acts indirectly by causing cell-cycle arrest at a stage where there is high degradation of the FLIP-TRAF2 complex. Second, the regulation of the proapoptotic Bcl-2 family member BAX occurs indirectly. Apoptosis signaling and caspase activation results in a confirmation change in the normally monomeric BAX, which exposes the BH3 domain of BAX, leading to dimerization and resistance to ubiquitin degradation. BAX then translocates into the mitochondria, resulting in the release of proapoptotic mitochondrial factors such as cytochrome c and second mitochondria-derived activator of caspase (SMAC). This results in the activation of caspase-9 and formation of the apoptosome and efficient apoptosis signaling. A third mechanism of the regulation of TRAIL signaling in the ubiquitin-proteasome pathway is mediated by the inhibitor of apoptosis proteins (IAP) E3 ligases. These IAPs can directly bind to caspases but also can act as ubiquitin ligases for caspases, resulting in the degradation of these caspases. IAP binding to caspases can be inhibited by SMAC, which exhibits a caspase-9 homology domain. The fourth mechanism for apoptosis activation by proteasome inhibitors is through the stabilization of the inhibitor of the kappaB (IkappaB)/NF-kappaB complex and prevention of nuclear translocation of the antiapoptosis transcription factor NF-kappaB. During TRAIL-DR4, DR5 signaling, this pathway is activated by interactions of activated Fas-associated death domain with activated receptor-
interacting protein
(RIP), which in turn activates NF-kappaB-inducing kinase and phosphorylates IkappaB. Therefore, the inhibition of IkappaB degradation blocks this RIP-mediated antiapoptosis signaling event. Last,
p53 protein
levels, and susceptibility to apoptosis, can be deregulated by the human homolog Hdm2 (Mdm2) E3 ligase. This process is inhibited by
p53
phosphorylation and by sequestration of Mdm2 by ARF. Better mechanisms to inhibit the ubiquitin-proteasome pathway targeted at the ubiquitin-proteasome degradation process itself, or more specifically at the E3 ligases known to modulate and downregulate proapoptosis pathways will lead to the enhancement of TRAIL apoptosis signaling and better cancer therapeutic outcomes act through this pathway.
...
PMID:Regulation of apoptosis proteins in cancer cells by ubiquitin. 1502 88
Pathogens exploit host machinery to establish an environment that favors their propagation. Because of their pivotal roles in cellular physiology, protein degradation pathways are common targets for viral proteins. Protein-linking integrin-associated protein and cytoskeleton 1 (PLIC1), also called ubiquilin, contains an amino-terminal ubiquitin-like (UBL) domain and a carboxy-terminal ubiquitin-associated (UBA) domain. PLIC1 is proposed to function as a regulator of the ubiquitination complex and proteasome machinery. Kaposi's sarcoma-associated herpesvirus (KSHV) contains a small membrane protein, K7, that protects cells from apoptosis induced by various stimuli. We report here that cellular PLIC1 is a K7-
interacting protein
and that the central hydrophobic region of K7 and the carboxy-terminal UBA domain of PLIC1 are responsible for their interaction. Cellular PLIC1 formed a dimer and bound efficiently to polyubiquitinated proteins through its carboxy-terminal UBA domain, and this activity correlated with its ability to stabilize cellular I kappa B protein. In contrast, K7 interaction prevented PLIC1 from forming a dimer and binding to polyubiquitinated proteins, leading to the rapid degradation of I kappa B. Furthermore, K7 expression promoted efficient degradation of the
p53 tumor suppressor
, resulting in inhibition of
p53
-mediated apoptosis. These results indicate that KSHV K7 targets a regulator of the ubiquitin- and proteasome-mediated degradation machinery to deregulate cellular protein turnover, which potentially provides a favorable environment for viral reproduction.
...
PMID:Kaposi's sarcoma-associated herpesvirus K7 protein targets a ubiquitin-like/ubiquitin-associated domain-containing protein to promote protein degradation. 1508 87
COP1 (constitutively photomorphogenic 1) is a RING-finger-containing protein that functions to repress plant photomorphogenesis, the light-mediated programme of plant development. Mutants of COP1 are constitutively photomorphogenic, and this has been attributed to their inability to negatively regulate the proteins LAF1 (ref. 1) and HY5 (ref. 2). The role of COP1 in mammalian cells is less well characterized. Here we identify the tumour-suppressor
protein p53
as a COP1-
interacting protein
. COP1 increases
p53
turnover by targeting it for degradation by the proteasome in a ubiquitin-dependent fashion, independently of MDM2 or Pirh2, which are known to interact with and negatively regulate
p53
. Moreover, COP1 serves as an E3 ubiquitin ligase for
p53
in vitro and in vivo, and inhibits
p53
-dependent transcription and apoptosis. Depletion of COP1 by short interfering RNA (siRNA) stabilizes
p53
and arrests cells in the G1 phase of the cell cycle. Furthermore, we identify COP1 as a
p53
-inducible gene, and show that the depletion of COP1 and MDM2 by siRNA cooperatively sensitizes U2-OS cells to ionizing-radiation-induced cell death. Overall, these results indicate that COP1 is a critical negative regulator of
p53
and represents a new pathway for maintaining
p53
at low levels in unstressed cells.
...
PMID:The ubiquitin ligase COP1 is a critical negative regulator of p53. 1510 85
The
p53
tumour suppressor exerts anti-proliferative effects, including growth arrest, apoptosis and cell senescence, in response to various types of stress. However,
p53
is a short-lived protein and its activity is maintained at low levels in normal cells. Numerous studies indicate that CBP/p300-mediated acetyl-transferase activity is critical for its role in both catalysing
p53
acetylation and activating
p53
-mediated function during stress response. Interestingly, two additional regulators have also been identified in the
p53
acetylation pathway. PID/MTA2 is a
p53
-
interacting protein
that induces
p53
deacetylation by recruiting the HDAC1 complex. Subsequent work has also identified Sir2alpha, a NAD-dependent histone deacetylase that can attenuate
p53
transcriptional activity through deacetylation. The prominence of deacetylase activity on
p53
certainly raises the defining question of its physiological purpose. It is likely that deacetylation proxides a quick acting mechanism to stop
p53
function once transcriptional activation of target genes is no longer needed. We present data indicating that both HDAC1 and Sir2alpha are critical for
p53
-dependent stress response. Furthermore, we also try to define the functional consequence of
p53
acetylation at the molecular level. Finally, we propose a model regarding the differential roles of HDAC1 and Sir2alpha in the regulation of
p53
function.
...
PMID:Dynamics of the p53 acetylation pathway. 1517 Dec 55
Beta-catenin is a potent oncogenic protein whose cytoplasmic accumulation is a frequent event in cancer cells. The level of beta-catenin is regulated by two mechanisms: the adenomatous polyposis coli/Axin/glycogen synthase kinase 3beta-dependent degradation pathway and the Siah-1/Siah
interacting protein
/Ebi-mediated degradation pathway. In this study, we have investigated the functional significance of
p53
-inducible human Siah-family protein expression in the regulation of beta-catenin activity. We show here by reverse-transcriptase polymerase chain reaction that two mRNA transcripts, designated human Siah-1 and Siah-1L, are generated from the human Siah-1 locus. Interestingly, the expression of Siah-1L was upregulated by
p53
, whereas human Siah-1 expression was constant. Furthermore, introduction of exogenous Siah-1L protein downregulated beta-catenin protein and promoted apoptosis induced by anticancer drugs in cancer cells that lack endogenous
p53
. Thus, Siah-1L represents a new member of the human Siah family that is induced in response to
p53
and plays an important role in the regulation of beta-catenin activity in tumor cells. These findings also suggest new strategies for restoring tumor suppressive pathways lost in cancer cells that have suffered
p53
inactivation.
...
PMID:Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner. 1532 81
Axin and
p53
are tumor suppressors, controlling cell growth, apoptosis, and development. We show that Axin interacts with homeodomain-
interacting protein
kinase-2 (HIPK2), which is linked to UV-induced
p53
-dependent apoptosis by interacting with, and phosphorylating Ser 46 of,
p53
. In addition to association with
p53
via HIPK2, Axin contains a separate domain that directly interacts with
p53
at their physiological concentrations. Axin stimulates
p53
-dependent reporter transcription in 293 cells, but not in 293T, H1299, or SaOS-2 cells that are defective in
p53
signaling. Axin, but not AxindeltaHIPK2, activates HIPK2-mediated
p53
phosphorylation at Ser 46, facilitating
p53
-dependent transcriptional activity and apoptosis. Specific knockdown of Axin by siRNA reduced UV-induced Ser-46 phosphorylation and apoptosis. Kinase-dead HIPK2 reduced Axin-induced
p53
-dependent transcriptional activity, indicating that Axin stimulates
p53
function through HIPK2 kinase activity. Interestingly, HIPK2deltaAxin that lacks its Axin-binding region acts as a dominant-positive form in
p53
activation, suggesting that the Axin-binding region of HIPK2 is a putative autoinhibitory domain. These results show that Axin acts as a tumor suppressor by facilitating
p53
function through integration of multiple factors.
...
PMID:Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. 1552 30
CHK2/hCds1 plays important roles in the DNA damage-induced cell cycle checkpoint by phosphorylating several important targets, such as Cdc25 and
p53
. To obtain a better understanding of the CHK2 signaling pathway, we have carried out a yeast two-hybrid screen to search for potential CHK2-interacting proteins. Here, we report the identification of the mitotic checkpoint kinase, TTK/hMps1, as a novel CHK2-
interacting protein
. TTK/hMps1 directly phosphorylates CHK2 on Thr-68 in vitro. Expression of a TTK kinase-dead mutant, TTK(D647A), interferes with the G(2)/M arrest induced by either ionizing radiation or UV light. Interestingly, induction of CHK2 Thr-68 phosphorylation and of several downstream events, such as cyclin B1 accumulation and Cdc2 Tyr-15 phosphorylation, is also affected. Furthermore, ablation of TTK expression using small interfering RNA results not only in reduced CHK2 Thr-68 phosphorylation, but also in impaired growth arrest. Our results are consistent with a model in which TTK functions upstream from CHK2 in response to DNA damage and suggest possible cross-talk between the spindle assembly checkpoint and the DNA damage checkpoint.
...
PMID:TTK/hMps1 participates in the regulation of DNA damage checkpoint response by phosphorylating CHK2 on threonine 68. 1561 21
The
p53 tumor suppressor
is a transcription factor that is activated by diverse genotoxic and cytotoxic stresses. Upon activation,
p53
prevents the proliferation of genetically unstable cells by regulating the expression of genes that initiate cell cycle arrest, apoptosis, and DNA repair. Consequently,
p53
must be kept inactive in unstressed cells as its inappropriate activation can cause premature senescence and death.
p53
inhibition occurs primarily through the E3 ubiquitin ligase, MDM2. Because MDM2 is also a p53 target gene, stresses paradoxically activate
p53
while simultaneously increasing MDM2 expression. Therefore, a challenge has been to explain how the abundant MDM2 is prevented from inhibiting
p53
, thus ensuring that
p53
can execute an appropriate stress response. Here we discuss a new mechanism for
p53
activation involving DNA damage-induced auto-degradation of MDM2. Our data reveal that DNA damage leads to the destabilization of MDM2, which correlates with
p53
stabilization and target gene induction. Conversely,
p53
levels and activity decrease when MDM2 returns to a more stable state later in the stress response. The destabilization of MDM2 is required for
p53
activation, as blocking MDM2 degradation via proteasome inhibition prevents
p53
transactivation in DNA-damaged cells by enabling MDM2 to bind and inhibit
p53
. MDM2 destabilization is controlled by DNA damage-activated post-translational modifications and by its own RING domain, implying a possible role for the RING domain-
interacting protein
, MDMX, in regulating MDM2 stability. We propose that accelerated degradation of MDM2 limits its binding to
p53
during a stress response and enables
p53
to accumulate and remain active, even as
p53
transcriptionally activates more MDM2. Thus, the induction of MDM2 RNA by activated
p53
may create a reserve of MDM2 that can inactivate
p53
once the DNA damage stimulus has abated and MDM2 is restabilized. As many tumors inactivate wild type
p53
through MDM2 overexpression, exploiting the pathways that trigger MDM2 auto-degradation may be an important new strategy for chemotherapeutic intervention.
...
PMID:A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. 1568 15
The stability of wild-type
p53
is critical for its apoptotic function. In some cancers, wild-type
p53
is inactivated by interaction with viral and cellular proteins, and restoration of its activity has therapeutic potential. Here, we identify homeobox Msx1 as a
p53
-
interacting protein
and show its novel function as a
p53
regulator. Overexpression of homeobox Msx1 induced apoptosis of cancer cells harboring nonfunctional wild-type
p53
and suppressed growth of human tumor xenografts in nude mice. The homeodomain of Msx1 functions as a protein-protein interacting motif rather than a DNA-binding domain and is essential for stabilization, nuclear accumulation, and apoptotic function of wild-type
p53
. The identification of a novel function of Msx1 as a
p53
regulator may open new avenues for developing improved molecular therapies for tumors with a nonmutational
p53
inactivation mechanism.
...
PMID:Homeobox Msx1 interacts with p53 tumor suppressor and inhibits tumor growth by inducing apoptosis. 1570 71
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>